Stock Track | Catalyst Pharmaceuticals Stock Soars 5.03% on Strong Full-Year 2024 Earnings

Stock Track

Mar 01, 2025

Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) surged 5.03% in post-market trading on Friday as the pharmaceutical company reported impressive financial results for the full year 2024, beating analyst estimates.

The company's revenue grew 24% year-over-year to $491.7 million, exceeding analyst expectations by 1.6%. Net income soared 130% to $163.9 million, and earnings per share (EPS) also surpassed estimates by 7%, reaching $1.38.

Analysts reacted positively to the strong results, with Oppenheimer raising its price target on Catalyst Pharmaceuticals to $32 from $31, maintaining an Outperform rating. Bank of America Securities also reiterated its Buy rating on the stock. The company's impressive profit margin of 33%, up from 18% in the previous year, further contributed to the stock's rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1152812815"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152812815\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152812815?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-01 04:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152812815","market":"us","top_or_hot":-1,"title":"Stock Track | Catalyst Pharmaceuticals Stock Soars 5.03% on Strong Full-Year 2024 Earnings","media":"Stock Track","content":"<p>Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) surged 5.03% in post-market trading on Friday as the pharmaceutical company reported impressive financial results for the full year 2024, beating analyst estimates.</p>\n\n<p>The company's revenue grew 24% year-over-year to $491.7 million, exceeding analyst expectations by 1.6%. Net income soared 130% to $163.9 million, and earnings per share (EPS) also surpassed estimates by 7%, reaching $1.38.</p>\n\n<p>Analysts reacted positively to the strong results, with Oppenheimer raising its price target on Catalyst Pharmaceuticals to $32 from $31, maintaining an Outperform rating. Bank of America Securities also reiterated its Buy rating on the stock. The company's impressive profit margin of 33%, up from 18% in the previous year, further contributed to the stock's rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Catalyst Pharmaceuticals Stock Soars 5.03% on Strong Full-Year 2024 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Catalyst Pharmaceuticals Stock Soars 5.03% on Strong Full-Year 2024 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-01 04:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) surged 5.03% in post-market trading on Friday as the pharmaceutical company reported impressive financial results for the full year 2024, beating analyst estimates.</p>\n\n<p>The company's revenue grew 24% year-over-year to $491.7 million, exceeding analyst expectations by 1.6%. Net income soared 130% to $163.9 million, and earnings per share (EPS) also surpassed estimates by 7%, reaching $1.38.</p>\n\n<p>Analysts reacted positively to the strong results, with Oppenheimer raising its price target on Catalyst Pharmaceuticals to $32 from $31, maintaining an Outperform rating. Bank of America Securities also reiterated its Buy rating on the stock. The company's impressive profit margin of 33%, up from 18% in the previous year, further contributed to the stock's rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPRX","symbol_name":"Catalyst Pharmaceutical Partners","start_time":0,"source_url":"","article_id":"1152812815","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152812815","pubTimestamp":1740775352,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Catalyst Pharmaceuticals  surged 5.03% in post-market trading on Friday as the pharmaceutical company reported impressive financial results for the full year 2024, beating analyst estimates.The company's revenue grew 24% year-over-year to $491.7 million, exceeding analyst expectations by 1.6%. Net income soared 130% to $163.9 million, and earnings per share  also surpassed estimates by 7%, reaching $1.38.Analysts reacted positively to the strong results, with Oppenheimer raising its pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"股票轨迹Catalyst Pharmaceuticals股价因2024年全年盈利强劲而飙升5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1},"content_text":"Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) surged 5.03% in post-market trading on Friday as the pharmaceutical company reported impressive financial results for the full year 2024, beating analyst estimates.\nThe company's revenue grew 24% year-over-year to $491.7 million, exceeding analyst expectations by 1.6%. Net income soared 130% to $163.9 million, and earnings per share (EPS) also surpassed estimates by 7%, reaching $1.38.\nAnalysts reacted positively to the strong results, with Oppenheimer raising its price target on Catalyst Pharmaceuticals to $32 from $31, maintaining an Outperform rating. Bank of America Securities also reiterated its Buy rating on the stock. The company's impressive profit margin of 33%, up from 18% in the previous year, further contributed to the stock's rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}